Olaratumab: en combinació amb doxorubicina per al tractament de pacients adults amb sarcoma de parts toves avançat, no candidats a tractament curatiu amb cirurgia o radioteràpia, i no tractats prèviament amb doxorubicina
Abstract
The first line treatment for advanced soft tissue sarcoma (SPT) in adults is the
anthracycline based chemotherapy, with a response rate of 10% to 30%. The objective of treatment is palliative and seeks to improve survival with quality of life. Until now, no trial has managed to compete with doxorubicin in terms of overall survival, despite being a 60-year drug. Olaratumab is a monoclonal antibody that binds specifically to the recombinant factor-derived α receptor (PDGFR-α) to the tumor cells and the stroma, inhibiting the growth of the tumor
Keywords
Olaratumab; Soft tissues; Palliative treatment
Bibliographic citation
Olaratumab: en combinació amb doxorubicina per al tractament de pacients adults amb sarcoma de parts toves avançat, no candidats a tractament curatiu amb cirurgia o radioteràpia, i no tractats prèviament amb doxorubicina. Barcelona: Servei Català de la Salut; 2018.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/3638This item appears in following collections
The following license files are associated with this item: